Supported by 14 clinical trials
Identified and isolated in 1999 and commericalised in 2004, the Lab4 probiotics consortium contains four proprietary bacteria strains – Lactobacillus acidophilus (CUL60), Lactobacillus acidophilus (CUL21), Bifidobacterium animalis subsp. lactis (CUL34) and Bifidobacterium bifidum (CUL20).
The Lab4 probiotics blend is supported by 14 clinical trials and a number of in vitro and in vivo studies across a wide range of conditions at doses ranging from 12.5 billion CFUs to 50 billion CFUs per day. The conditions studied to date include C. difficile, using probiotics alongside antibiotics, irritable bowel syndrome (IBS), immunity, upper respiratory tract infection (URTI), mood and performance.